In this framework, the already mentioned strand of phytotherapeutic research, so far quite active only for MMPs and AMPs, are promising, along with the design of new alarmins‐targeting monoclonal antibodies and alarmins‐based anti‐melanoma vaccines, and the progress of pioneering miRNAs‐based drugs. This evidence concerns the gene ADSL and melanoma.